Receptor tyrosine kinases in breast tumor progression and therapeutic resistance Tumor suppressors & oncogenes in breast cancer Mouse models of breast cancer

Hatakeyma, J., Wald, J.H, Rafidi, H., Cuevas, A., Sweeney, C. and Carraway, K.L. III. The ER structural protein Rtn4a stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3. 2016 Science Signaling, Jun 28;9(434):ra65. *Cover of journal* Rungrojsakul, M., Katekunlaphan, T., Saiai, A., Ampasavate, C., Okonogi, S, Sweeney, C. and Anuchapreeda, S. Down-regulatory mechanism of mammea E/BB from Mammea siamensis seed extract on Wilms' Tumor 1 expression in K562 cells. 2016. BMC Complementary and Alternative Medicine, May 18;16(1):130. Rowson-Hodel, A.R., Berg, A.L., Wald, J.H, Hatakeyama, J., VanderVorst, K., Curiel, D.A., Leon, L.J., Sweeney, C. and Carraway, K.L. III. Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells. 2016 Cancer Letters, May 28;375(1):62-72. Amir, S., Simion, C., Umeh, M., Krig, S., Moss, T., Carraway, K.L. III and Sweeney, C. Regulation of the T-box transcription factor TBX3 by the tumor suppressor microRNA-206 in breast cancer. 2016 British Journal of Cancer, May 10;114(10):1125-34. Yokdang, N., Hatakeyama, J., Wald, J.H., Simion, C., Tellez, J.D., Chang, D.Z., Swamynathan, M.M., Chen, M., Murphy. W.J., Carraway, K.L. III and Sweeney, C. LRIG1 opposes epithelial to mesenchymal transition and inhibits invasion of basal-like breast cancer cells. 2016 Oncogene, Jun 2;35(22):2932-47. Morrison, M.M., Williams, M.M., Vaught, D.B., Hicks, D., Lim, J., McKernan, C., Aurisicchio, L., Cennaro, G., Simion, C., Sweeney, C. and Cook, R.S. Decreased Lrig1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 up-regulation and increased growth. 2016 Oncogene, Mar 3;35(9):1206. Bekki, K., Vogel, H., Li, W., Ito, T., Sweeney, C., Haarmann-Stemman, T., Matsumura, F., Vogel, C. The Aryl Hydrocarbon receptor (AhR) mediates resistance to apoptosis in breast cancer cells. 2015 Pesticide Biochemistry and Physiology, 2015 May;120:5-13. Candas, D., Lu, C.L., Fan, M., Chuang, F.Y.S., Sweeney, C., Borowsky, A.D., and Li, J.J. Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells. 2014 Cancer Research, Dec 15;74(24):7498-509. *Top Story, Mammary Cell News, Nov. 13th 2014.* Simion, C. Prieto, M. Sweeney, C. “The LRIG family – enigmatic regulators of growth factor receptor signaling”, 2014 Endocrine Related Cancer, Dec; 21(6):R431-R443. *Invited peer-reviewed review* Frietze, S., Geen, H., Simion, C., Littlepage, L.E., Sweeney, C., Farnham, P.J. and Krig, S.R. Analysis of ZNF217 chromatin occupancy reveals an association with ER-positive breast cancer. 2014 BMC Genomics, Jun 24;15:520. Printsev, I. Yen, L, Sweeney, C. and Carraway, K.L. III. Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination. 2014 J.Biol.Chem March 21; 289(12):8570-8. Rafidi, H.R., Mercado, F.M., Astudillo, M., Fry, W.H., Carraway, K.L. III and Sweeney, C. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action towards ErbB receptor tyrosine kinases is opposed by Leucine-rich repeat and immunoglobulin domain-containing protein-3 (Lrig3). 2013 J. Biol. Chem. July 26, 288(30): 21593-605. Littlepage, L.E., Adler, A.S., Kouros-Mehr, H., Huang, G., Chou, J., Krig, S.R., Griffith, O.L., Korkola, J.E., Qu, K., Lawson, D.A., Xue, Q., Sternlicht, M.D., Dijkgraaf, G.J.P., Yaswen, P., Rugo, H.S., Sweeney, C., Collins, C.C., Gray, J.W., Chang, H.Y., Werb, Z. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. 2012 Cancer Discovery, Jul;2(7):638-51. Krig, S.R., Frietze, S., Simion, C, Miller, J.K., Fry, W.H., Rafidi, H., Kotelawala, L., Qi, L., Griffith, O., Gray, J.W., Carraway, K.L. III and Sweeney C. Lrig1 is an estrogen regulated growth suppressor and correlates with longer relapse-free survival in ERa-positive breast cancer. 2011 Molecular Cancer Research, 9(10):1406-17. *Highlighted by Connexon Creative Mammary Cell News, August 11 2011* Vogel, C., Li, W., Wu, D., Miller, J.K., Sweeney, C., Lazennec, G., Fujisawa, Y., and Matsumura, F. Interaction of Aryl hydrocarbon receptor and NF-B subunit RelB in breast cancer is associated with Interleukin-8 overexpression. 2011 Archives of Biochemistry and Biophysics, 512(1):78-86. Fry WH, Simion C, Sweeney C., Carraway KL III. Quantity Control of the ErbB3 Receptor Tyrosine Kinase at the Endoplasmic Reticulum. 2011 Molecular and Cellular Biology, 31(14):3009-18. Semsri, S., Krig, S.R., Kotelawala, L., Sweeney, C.*, and Anuchapreeda, S*. Inhibitory mechanism of pure curcumin on Wilm’s tumor 1 (WT1) gene expression through the PKCa signaling pathway. 2011 Febs Letters, 585(14):2235-42. * co-Corresponding authors Krig, S.R., Miller, J.K., Frietze, S., Beckett, L.A., Neve, R., Farnham, P.J., Yaswen, P. and Sweeney, C. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. 2010 Oncogene, Oct 7;29(40):5500-10. *Highlighted by Connexon Creative Mammary Cell News, July 29 2010* Ingalla, E.Q., Miller, J.K., Wald, J.H., Workman, H.C., Kaur, R.P, Yen, L., Fry, W.H., Borowsky, A.D., Young, L.J.T., Sweeney, C., and Carraway, K.L. III. Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors. 2010. J. Biol. Chem, Sep 10;285(37):28691-7. Silva, A., Fry, W.H.D., Sweeney, C. and Trainor, B.C. Effects of photoperiod and experience on aggressive behavior in female California mice. 2010 Behavioral Brain Research, 208(2):528-34.